KR20160002539A - Composition containing amorpha fruticosa extract - Google Patents
Composition containing amorpha fruticosa extract Download PDFInfo
- Publication number
- KR20160002539A KR20160002539A KR1020140081151A KR20140081151A KR20160002539A KR 20160002539 A KR20160002539 A KR 20160002539A KR 1020140081151 A KR1020140081151 A KR 1020140081151A KR 20140081151 A KR20140081151 A KR 20140081151A KR 20160002539 A KR20160002539 A KR 20160002539A
- Authority
- KR
- South Korea
- Prior art keywords
- composition
- extract
- skin
- fraction
- present
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 101
- 239000000284 extract Substances 0.000 title claims abstract description 59
- 240000002066 Amorpha fruticosa Species 0.000 title abstract description 4
- 235000004047 Amorpha fruticosa Nutrition 0.000 title abstract description 4
- 230000037303 wrinkles Effects 0.000 claims abstract description 11
- 230000003712 anti-aging effect Effects 0.000 claims abstract description 9
- 230000000694 effects Effects 0.000 claims description 41
- 235000021028 berry Nutrition 0.000 claims description 29
- 230000015572 biosynthetic process Effects 0.000 claims description 20
- 238000000034 method Methods 0.000 claims description 18
- 241000254171 Curculionidae Species 0.000 claims description 16
- 230000014509 gene expression Effects 0.000 claims description 15
- 239000004480 active ingredient Substances 0.000 claims description 14
- 108010067372 Pancreatic elastase Proteins 0.000 claims description 13
- 102000016387 Pancreatic elastase Human genes 0.000 claims description 13
- 239000002537 cosmetic Substances 0.000 claims description 12
- 230000003020 moisturizing effect Effects 0.000 claims description 11
- 102000005741 Metalloproteases Human genes 0.000 claims description 9
- 108010006035 Metalloproteases Proteins 0.000 claims description 9
- 238000003786 synthesis reaction Methods 0.000 claims description 8
- 108010063290 Aquaporins Proteins 0.000 claims description 7
- 230000037394 skin elasticity Effects 0.000 claims description 7
- 102000010637 Aquaporins Human genes 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 229950004354 phosphorylcholine Drugs 0.000 claims description 3
- 230000037373 wrinkle formation Effects 0.000 claims description 3
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims 1
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- YHHSONZFOIEMCP-UHFFFAOYSA-O phosphocholine Chemical compound C[N+](C)(C)CCOP(O)(O)=O YHHSONZFOIEMCP-UHFFFAOYSA-O 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 5
- 210000003491 skin Anatomy 0.000 description 38
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000009472 formulation Methods 0.000 description 16
- 238000000605 extraction Methods 0.000 description 14
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 13
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 13
- 241001504654 Mustela nivalis Species 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 12
- 241000282341 Mustela putorius furo Species 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 9
- 108010035532 Collagen Proteins 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- 239000006071 cream Substances 0.000 description 9
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 8
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 8
- 230000032683 aging Effects 0.000 description 8
- 210000002510 keratinocyte Anatomy 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 7
- 102000029816 Collagenase Human genes 0.000 description 7
- 108060005980 Collagenase Proteins 0.000 description 7
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 7
- 229960002424 collagenase Drugs 0.000 description 7
- 239000008187 granular material Substances 0.000 description 7
- 239000008213 purified water Substances 0.000 description 7
- 108010014258 Elastin Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000013329 compounding Methods 0.000 description 6
- 229940088598 enzyme Drugs 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 108090000991 Aquaporin 3 Proteins 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000008591 skin barrier function Effects 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 229940058015 1,3-butylene glycol Drugs 0.000 description 4
- 102000004363 Aquaporin 3 Human genes 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000016942 Elastin Human genes 0.000 description 4
- 102000013382 Gelatinases Human genes 0.000 description 4
- 108010026132 Gelatinases Proteins 0.000 description 4
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 4
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- -1 blockers Substances 0.000 description 4
- 235000019437 butane-1,3-diol Nutrition 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 229920002549 elastin Polymers 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000000401 methanolic extract Substances 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000009759 skin aging Effects 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102100028314 Filaggrin Human genes 0.000 description 3
- 101710088660 Filaggrin Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 101000851058 Homo sapiens Neutrophil elastase Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100033174 Neutrophil elastase Human genes 0.000 description 3
- 235000002789 Panax ginseng Nutrition 0.000 description 3
- 108010050808 Procollagen Proteins 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 210000004207 dermis Anatomy 0.000 description 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 210000000434 stratum corneum Anatomy 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000000375 suspending agent Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102100033167 Elastin Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- ACFGRWJEQJVZTM-LEJBHHMKSA-L Magnesium L-ascorbic acid-2-phosphate Chemical compound [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O ACFGRWJEQJVZTM-LEJBHHMKSA-L 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 239000004902 Softening Agent Substances 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 102100033142 Transcription factor 20 Human genes 0.000 description 2
- 101710119730 Transcription factor 20 Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012620 biological material Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002034 butanolic fraction Substances 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- YRQNKMKHABXEJZ-UVQQGXFZSA-N chembl176323 Chemical compound C1C[C@]2(C)[C@@]3(C)CC(N=C4C[C@]5(C)CCC6[C@]7(C)CC[C@@H]([C@]7(CC[C@]6(C)[C@@]5(C)CC4=N4)C)CCCCCCCC)=C4C[C@]3(C)CCC2[C@]2(C)CC[C@H](CCCCCCCC)[C@]21C YRQNKMKHABXEJZ-UVQQGXFZSA-N 0.000 description 2
- 230000011382 collagen catabolic process Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000003912 environmental pollution Methods 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 239000002038 ethyl acetate fraction Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 239000004088 foaming agent Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 239000002044 hexane fraction Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 102000007236 involucrin Human genes 0.000 description 2
- 108010033564 involucrin Proteins 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- PYJNAPOPMIJKJZ-UHFFFAOYSA-N phosphorylcholine chloride Chemical compound [Cl-].C[N+](C)(C)CCOP(O)(O)=O PYJNAPOPMIJKJZ-UHFFFAOYSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000003352 sequestering agent Substances 0.000 description 2
- 230000037384 skin absorption Effects 0.000 description 2
- 231100000274 skin absorption Toxicity 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- BWSWZBCSFZAYOB-CABCVRRESA-N (2s,4r)-1-dodecanoyl-4-hydroxypyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCC(=O)N1C[C@H](O)C[C@H]1C(O)=O BWSWZBCSFZAYOB-CABCVRRESA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- VKUYLANQOAKALN-UHFFFAOYSA-N 2-[benzyl-(4-methoxyphenyl)sulfonylamino]-n-hydroxy-4-methylpentanamide Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N(C(CC(C)C)C(=O)NO)CC1=CC=CC=C1 VKUYLANQOAKALN-UHFFFAOYSA-N 0.000 description 1
- RFVNOJDQRGSOEL-UHFFFAOYSA-N 2-hydroxyethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCO RFVNOJDQRGSOEL-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- YHBDGLZYNIARKJ-GUBZILKMSA-N Ala-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](C)N YHBDGLZYNIARKJ-GUBZILKMSA-N 0.000 description 1
- 241000212978 Amorpha <angiosperm> Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 102100027995 Collagenase 3 Human genes 0.000 description 1
- 108050005238 Collagenase 3 Proteins 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000127225 Enceliopsis nudicaulis Species 0.000 description 1
- IMROMDMJAWUWLK-UHFFFAOYSA-N Ethenol Chemical group OC=C IMROMDMJAWUWLK-UHFFFAOYSA-N 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108700010340 Leishmanolysins Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102100030417 Matrilysin Human genes 0.000 description 1
- 108090000855 Matrilysin Proteins 0.000 description 1
- 108010076557 Matrix Metalloproteinase 14 Proteins 0.000 description 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 description 1
- 102100030216 Matrix metalloproteinase-14 Human genes 0.000 description 1
- 102100024129 Matrix metalloproteinase-24 Human genes 0.000 description 1
- 108050005214 Matrix metalloproteinase-24 Proteins 0.000 description 1
- 102100024131 Matrix metalloproteinase-25 Human genes 0.000 description 1
- 102000001776 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 102000036436 Metzincins Human genes 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 102100030411 Neutrophil collagenase Human genes 0.000 description 1
- 101710118230 Neutrophil collagenase Proteins 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 102100030416 Stromelysin-1 Human genes 0.000 description 1
- 101710108790 Stromelysin-1 Proteins 0.000 description 1
- 102100028848 Stromelysin-2 Human genes 0.000 description 1
- 101710108792 Stromelysin-2 Proteins 0.000 description 1
- 102100028847 Stromelysin-3 Human genes 0.000 description 1
- 108050005271 Stromelysin-3 Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 102000036861 Zinc-dependent endopeptidases Human genes 0.000 description 1
- 108091006982 Zinc-dependent endopeptidases Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000012223 aqueous fraction Substances 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000008687 biosynthesis inhibition Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 108090000440 matrix metalloproteinase 25 Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- CKQVRZJOMJRTOY-UHFFFAOYSA-N octadecanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCCCC(O)=O CKQVRZJOMJRTOY-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 235000019449 other food additives Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 235000012736 patent blue V Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 238000007805 zymography Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
Description
The present invention relates to an anti-aging or moisturizing composition comprising a ferret extract or a fraction thereof.
Skin aging processes are generally caused by intrinsic aging and photoaging (Gilchrest, 1989; Ma et al., 2001; Jenkins, 2002). Endogenous aging is caused by decreasing the secretion of various hormones that regulate metabolism over time, decreasing the function of immune cells and the activity of cells, decreasing the biosynthesis of immune proteins and biologic proteins necessary for the living body, The amount of ultraviolet ray reaching the surface of the sun ray is increased due to destruction of the ozone layer and the environmental pollution is further intensified, so that the thickness of the skin is reduced, the wrinkles are increased and the elasticity is decreased, It also causes various changes such as an increase in black spots. The skin consists of the epidermis, epidermis dermis boundary, dermis, and subcutaneous fat layer in order. The epidermis is divided into stratum corneum, granular layer, superficial layer and basal layer in order from the outside. Cells of stratum corneum act like bricks, Intercellular lipids act as a mortar and constitute skin barrier (J. Invest. Dermatol. 80 (Suppl.), 44-49, 1983). In addition, a healthy human keratinocyte has a high concentration of natural moisturizing factor (NMF) to help maintain moisture in the skin. For example, substances such as amino acids are water-soluble, (J. Invest. Dermatol. 54, 24-31, 1970). Recently known Aquaporin proteins are known to have 13 types and are known to play important role in skin barrier function, stratum corneum water supply and wound healing as small neutral solutes such as glycerol, urea, and water. In particular, Aquaporin 3 protein has been shown to exhibit key functions in the skin (Exp Dermatol. 20, 595-599, 2011).
However, as it is nowadays, there is a tendency to adjust the temperature of the air / heating due to the change of environment or life pattern, the stress caused by various stresses and environmental pollution in the social life, frequent washing according to make- Due to various causes such as aging of the skin, the skin becomes dry, the surface becomes rough, the skin becomes loose, the moisture is lost, and the appearance of the skin does not appear, and thus the need for a skin moisturizer increases . Excessive physical and chemical stimuli from the outside, ultraviolet rays, stress and nutritional deficiencies lower the normal functions of the skin and promote skin aging phenomenon such as loss of elasticity, keratinization and wrinkle formation. Particularly, It is severely damaged.
The extracellular matrix of the dermis consists mainly of structural proteins such as collagen, proteoglycan and glycoprotein, and timely degradation is a necessary condition for the absorption and reshaping of tissues. Matrix metalloproteinases (MMPs) are responsible for the degradation of extracellular matrix. MMP is a zinc-dependent endopeptidase and was first discovered in 1962 as a tail degrading enzyme in tadpoles (Proc Natl Acad Sci USA 48 (6): 1014-22, 1962) and in humans in 1968 (Biochim Biophys Acta 151 (3): 637-45, 1968) and TIMP (Tissue Inhibitor of Matrix Metalloproteinases) as an endogenous inhibitor. MMP-1, MMP-8, and MMP-13), gelatinase (MMP-2 and MMP-9), stromelysins (MMP-3, MMP-10 and MMP-11), and matrilysin (MMP-12), membrane-type MMPs (MMP-14 ~ 17, MMP-24, MMP-25) Zero includes Tumor Necrosis Factor (TNF), Extracellular Metrix Metalloproteinase Inducer (EMFRIN) and TCF20 (Transcription Factor 20). If the expression and activity of the MMP is inappropriately controlled by ultraviolet rays and internal and external factors, the skin is seriously damaged and the skin aging phenomenon is promoted, and thus it is attracting attention as a main target of prevention and improvement of skin aging.
An object of the present invention is to provide a composition for anti-aging or moisturizing derived from natural origin.
In order to accomplish the above object, one aspect of the present invention provides a composition for anti-aging comprising a weevil berry extract or a fraction thereof as an active ingredient.
One aspect of the present invention also provides a moisturizing composition comprising a ferret extract or a fraction thereof as an active ingredient.
The composition of the present invention contains an actinicidal fermented extract as an active ingredient, and has effects such as anti-aging and moisturizing. The composition of the present invention can inhibit the biosynthesis of metalloprotease, gelatinease or elastase, for example, and can lower its activity, thereby improving aging by improving wrinkles of skin, alleviation of skin wrinkles, improvement of elasticity, It can be prevented or delayed. The compositions of the present invention can also promote the synthesis of, for example, pilar green or inboluclease and enhance their activity, which can bring about skin moisturizing effects and can enhance skin barrier, And the like. In addition, the composition of the present invention contains natural substances obtained from nature as an effective ingredient, and thus has a small side effect when applied to a human body, and has an advantage of being resistant to long-term use, and is excellent in skin stability.
FIG. 1 is a graph showing effects of collagenase I (MMP-1) on the expression of collagen and the effect of collagenase when treated with ultraviolet irradiation on Feline extract or its fractions.
FIG. 2 shows the effect of treatment with TNF-.alpha. On the expression of collagenase I (MMP-1) when treated with a ferret extract or a fraction thereof.
FIG. 3 shows the effect of ultraviolet irradiation on the biosynthesis of gelatinase (MMP-2, MMP-9) when treating a ferret extract or its fraction.
FIG. 4 shows the effect of ultraviolet irradiation on the activity of gelatinase (MMP-2, MMP-9) when treated with a ferret extract or a fraction thereof.
FIG. 5 shows the effect of the ferret extract or fraction thereof on elastase activity.
Fig. 6 shows the effect of the ferret extract or its fractions on the biosynthesis of pilagreen and inboluclease.
Fig. 7 shows the effects of the weevil berry extract or its fractions on the expression of the aquaporin gene.
The present invention relates to an anti-aging composition comprising, as an active ingredient, a weevil leaf extract in one aspect.
The term " Amorpha " fruticosa "is a deciduous shrub with dicotyledonous rosemary beans and is sometimes referred to as" sideways "or" twisted "and is native to North America. The leaves are like cedar trees, and the seeds are similar to the pine cones. It is about 3m in height, and there are hairs on tree branches, but it gradually disappears as it grows. Leaves are alternate and once folded leaves. Small leaves are 11 ~ 25, ovate or oval, with flat edges. Flowers bloom in May-June, purplish sky blue, strong fragrance. The fruit is fruitful in September and is a conclusion. The fruit contains one seed and has a kidney shape.
The weevil broth used in the present specification is not limited to the method of obtaining it, and it may be cultivated or purchased and used. In addition, as used herein, weasel copys can use some or all of the overhead or underground portions of weasel copious herbaceous plants. In one embodiment of the present invention, seeds (fruit) among the above-ground portions (leaves, twigs, stems, etc.) of the weevil broth are used, but the present invention is not limited thereto.
As used herein, the term " active ingredient " alone refers to an ingredient that exhibits the desired activity or that can exhibit activity with a carrier that is not itself active.
As used herein, the term " anti-aging " refers to an effect of slowing down, preventing or preventing the aging process generally known in the art. Specifically, it effectively suppresses the expression of collagenase in skin, Enhancing skin elasticity, improving wrinkles, etc., or inhibiting the synthesis of metalloprotease, gelatinase, or elastase, or inhibiting their activity, thereby delaying or preventing the generally known aging phenomenon But is not limited thereto.
As used herein, the " weasel berry " extract may be obtained using any extraction method known in the art without limitation. Specifically, the weevil berry extract comprises but is not limited to an extract of a solvent selected from the group consisting of water, C1-C6 alcohol, and combinations thereof. The ferret extract of the present invention can be obtained, for example, but not limited to the following. When the weedy berry is extracted with a solvent, it can be extracted by adding about 5 to 15 times the solvent of the weedy berry, and specifically extracting it by adding about 10 times the solvent. However, the present invention is not limited thereto. The extraction may be performed by heat extraction, cold extraction, reflux cooling extraction, ultrasonic extraction or the like, and there is no limitation as long as it is an extraction method that is obvious to a person skilled in the art. The extraction may be carried out at room temperature, but may be carried out under heating or extraction at a temperature of about 40 to 100 ° C for more efficient extraction, but is not limited thereto. The extraction time may be about 2 to 4 hours, but it is not limited thereto and may be varied depending on conditions such as extraction solvent and extraction temperature. The extraction may be carried out one or more times several times to obtain a larger amount of the active ingredient, for example, one to five or three consecutive extracts may be used.
In a composition according to one aspect of the present invention, the weevil berry extract may be a methanol extract of a weevil berry and a methanol extract of a weevil berry seed (berry).
As used herein, the term " weaning fraction " means a fraction obtained by further extracting a weedy fermentation extract obtained by a method as described above. Methods known in the art for obtaining such fractions can be used without limitation. Specifically, the fraction may be a fraction of an organic solvent obtained by further extracting a weedy berry extract with an organic solvent having a low polarity. For example, the organic solvent may be hexane, methylene chloride, ethyl acetate, n-butanol And so on. The extract or the fraction thereof may be used as it is, or may be used as an extract form by concentration after filtration, and may be used as a form of a lyophilizate by concentration and freeze-drying.
In a composition that is an aspect of the invention, the weasel fraction may be a methylenecryl chloride fraction, a hexane fraction, an ethyl acetate fraction, a butanol fraction, or a water fraction, and may be a fraction of a weevil sari (fruit).
In a composition according to one aspect of the present invention, the composition can prevent wrinkles of the skin, delay the generation of wrinkles of the skin, or prevent wrinkles of the skin.
In one aspect of the present invention, the composition can improve skin elasticity.
In one aspect of the present invention, the composition may inhibit the synthesis of metalloprotease, gelatinease or elastase, or inhibit their activity.
The collagen produced in the fibroblasts of the dermal layer of the skin is a major component of the extracellular matrix and plays an important role in securing the mechanical rigidity of the skin, inducing the resistance of connective tissues, supporting tissue binding, and supporting cell adhesion . However, as the aging progresses, the function of fibroblasts is lowered, the amount of collagen is decreased, and the expression of matrix metalloproteinase (MMP), an enzyme that degrades collagen, is promoted, thereby promoting collagen reduction.
Elastin is a factor that affects the maintenance of elasticity of the skin. It forms a matrix of skin by forming crosslinks with collagen. Elastin is synthesized in cells as a polypeptide called tropoelastin and then has secondary or three dimensional elasticity through cross-linking of extracellular tropoelastin. However, as aging progresses, the deficiency and aggregation of elastin fibers or the activity of elastase, elastase, sharply increases and breaks the network structure of elastin, thereby wrinkling the skin and reducing skin elasticity.
The composition, which is an aspect of the present invention, can also control biomaterials such as enzymes or proteins involved in up-stream related to the synthesis or activity of metalloprotease, gelatinease or elastase.
In another aspect, the present invention relates to a moisturizing composition comprising a weevil berry extract as an active ingredient. The composition of the present invention can enhance skin barrier function and induce differentiation of dermal keratinocytes. Therefore, it can be usefully used for preventing, improving or treating dry skin, atopy or psoriasis caused by incomplete epidermal differentiation.
A composition that is an aspect of the present invention can promote the synthesis of pillar green or phosphorylcholine or enhance their activity.
A composition that is an aspect of the present invention may also increase the expression of aquaporin.
The composition, which is an aspect of the present invention, can also regulate biomaterials such as up-stream-related enzymes and proteins related to the synthesis or activity of pilar green or phosphorylcholine, -stream) can be controlled.
A composition that is an aspect of the present invention may comprise from 0.001 to 10% by weight of the extract of Weasell, based on the total weight of the composition. If the content of the above-mentioned weedy berry extract is less than 0.001% by weight, the above-mentioned various effects are insignificant. If the content exceeds 10% by weight, the effect of the content of other ingredients is affected . In view of the above, the composition of the present invention may contain 0.001 to 10% by weight, 0.005 to 9% by weight, 0.01 to 8% by weight, 0.05 to 7% by weight or 0.1 to 6% by weight of a weevil sari extract.
In one aspect of the invention, the composition may be a cosmetic composition.
When the composition for external application for skin according to the present invention is formulated in the form of a cosmetic composition, it may be formulated into cosmetic formulations such as softening lotion, convergent lotion, nutritional lotion, eye cream, nutritional cream, massage cream, cleansing cream, cleansing foam, cleansing water, powder, essence or pack And the formulations thereof are not particularly limited. In addition, the composition according to the present invention can also be used as a lubricant, an organic solvent, a solubilizer, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, The active ingredient may be combined with any other ingredients commonly used in cosmetics, such as ionic emulsifiers, fillers, sequestering agents, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, And may contain adjuvants commonly used in the same cosmetic or dermatological fields. Such adjuvants are introduced in amounts commonly used in the cosmetics or dermatological fields. In addition, the composition of the present invention may contain a skin absorption promoting substance to increase the skin improving effect.
In one aspect of the present invention, the composition may be a composition for external application to the skin.
The composition of the present invention may be a composition for external application for skin, and more specifically, it may be used as a composition for external application for skin for antioxidant, which can provide an excellent antioxidative effect by inhibiting the oxidation of DPPH which is an organic radical. In addition, the composition of the present invention can be used as an anti-aging external composition for skin, which effectively inhibits the expression of collagenase in the skin, thereby reducing collagen degradation in the skin, thereby enhancing skin elasticity and improving wrinkles. In addition, the composition of the present invention can be used as a composition for external application for skin whitening, and it can provide an excellent whitening effect by inhibiting the production of melanin. Furthermore, the composition of the present invention can be used as a composition for external application for moisturizing skin, which can enhance the skin barrier function and induce differentiation of dermal keratinocytes. Therefore, it can be effectively used as a composition for external application for skin, which prevents or improves skin dryness or psoriasis caused by incomplete epidermal differentiation.
When the composition for external application for skin according to the present invention is formulated in the form of a cosmetic composition, it may be formulated into cosmetic formulations such as softening lotion, convergent lotion, nutritional lotion, eye cream, nutritional cream, massage cream, cleansing cream, cleansing foam, cleansing water, powder, essence or pack And the formulations thereof are not particularly limited. In addition, the composition according to the present invention can also be used as a lubricant, an organic solvent, a solubilizer, a thickening agent, a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, The active ingredient may be combined with any other ingredients commonly used in cosmetics, such as ionic emulsifiers, fillers, sequestering agents, chelating agents, preservatives, vitamins, blockers, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, And may contain adjuvants commonly used in the same cosmetic or dermatological fields. Such adjuvants are introduced in amounts commonly used in the cosmetics or dermatological fields. In addition, the composition of the present invention may contain a skin absorption promoting substance to increase the skin improving effect.
In one aspect of the present invention, the composition may be a pharmaceutical composition.
When the composition according to the present invention is applied to medicines, it may be formulated into an oral or parenteral dosage form in the form of solid, semi-solid or liquid by adding an inorganic or organic carrier to the composition as an active ingredient.
Examples of the agent for oral administration include tablets, pills, granules, soft capsules, powders, fine granules, powders, emulsions, syrups and pellets. Examples of the parenteral administration agent include injections, drops, ointments, lotions, sprays, suspensions, emulsions, suppositories, and the like. In order to formulate the active ingredient of the present invention, it can be easily formulated according to the conventional method. Surfactants, excipients, coloring agents, spices, preservatives, stabilizers, buffering agents, suspending agents and other adjuvants can be suitably used.
The pharmaceutical composition according to the present invention may be administered orally, parenterally, rectally, topically, transdermally, intravenously, intramuscularly, intraperitoneally, subcutaneously and the like.
In addition, the dosage of the active ingredient will depend on the age, sex, body weight of the subject to be treated, the particular disease or condition to be treated, the severity of the disease or condition, the route of administration and the judgment of the prescriber. Dosage determinations based on these factors are within the level of those skilled in the art. Typical dosages are from 0.001 mg / kg / day to 2000 mg / kg / day, more specifically from 0.5 mg / kg / day to 1500 mg / kg / day.
In one aspect of the invention, the composition may be a health food composition. The composition according to the present invention provides various types of food additives or functional foods containing them. It can be processed into fermented milk, cheese, yogurt, juice, probiotic agent and health supplement food including the above composition, and it can be used in various other food additives.
In one embodiment, the composition may contain other ingredients or the like that can give synergistic effects to the main effect within a range that does not impair the intended main effect of the present invention. For example, additives such as perfume, coloring agent, bactericide, antioxidant, preservative, moisturizing agent, thickening agent, inorganic salt, emulsifier and synthetic polymer substance may be further added for improvement of physical properties. In addition, it may further contain auxiliary components such as water-soluble vitamins, oil-soluble vitamins, polymer peptides, polymeric polysaccharides and seaweed extract. The above components may be mixed and selected without difficulty by those skilled in the art depending on the purpose of formulation or use, and the amount thereof may be selected within a range that does not impair the objects and effects of the present invention. For example, the addition amount of the above components may be in the range of 0.01 to 5% by weight, more specifically 0.01 to 3% by weight, based on the total weight of the composition.
The composition according to the present invention may be in various forms such as a solution, an emulsion, a viscous mixture, a tablet, a powder, etc., and may be administered by various methods such as simple drinking, injection administration, spraying or squeezing.
Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for illustrating the present invention and that the scope of the present invention is not construed as being limited by these embodiments.
The weevi berry of the following examples was used to grow in the Daegwallyeong highland.
[ Example 1] Production of weevil sari extract
100 g of weevil sari seeds were soaked in 1 L of 100% methanol and refluxed for 3 hours. This extraction was repeated three times, and the extract was dried under reduced pressure and concentrated to obtain 14.7 g of a concentrate.
[ Example 2] From weasel berry extract Fraction Produce
The methanol extract of the weedy berry seeds prepared in Example 1 was fractionated according to the step of solvent fractionation according to the general polarity. The methanol extract (10 g) was suspended in 500 ml of water, extracted with methylene chloride by shaking, and then the methylene chloride layer was separated. After two more fractions, the methylene chloride layers were combined and dried under reduced pressure to obtain methylene chloride fraction (< 2M >). The remaining water layer was successively fractionated with hexane (<2H>), ethyl acetate (<2E>), and butanol (<2B>). The upper fraction was concentrated under reduced pressure to obtain 0.8 g of methylene chloride fraction, 1.1 g of hexane fraction, 2.1 g of ethyl acetate fraction and 2.5 g of butanol fraction.
[ Experimental Example 1] Matrix by UV Metalloproteinase -One ( MMP -1) to inhibit biosynthesis and inhibition of collagen degradation
Human fibroblasts (Lonza, Switzerland), a primary cell directly isolated from the neonatal foreskin, were cultured in a 48-well plate incubator at a concentration of 10 4 , irradiated with ultraviolet B at 30 mJ / cm 2 after 24 hours The test substances in Table 1 were each replaced with a medium containing 10 ug / ml. On the second day of culture, the supernatant was harvested and the amount of MMP-1 produced was quantified using the ELISA (AP biotech RPN2610) method. The same supernatant was also used to quantify the remaining undissociated amount of procollagen using the ELISA (Takara MK101) method. Each value was expressed as a relative value with a value of the control group irradiated with only the ultraviolet ray B as 100 (Table 1 and Fig. 1).
As a result, as shown in Table 1 and Fig. 1, the treatment of the weedy berry extract or its fraction reduced the biosynthesis of matrix metalloprotease (MMP), a type I collagenase, and thus prevented the degradation of procollagen And it was found.
[ Experimental Example 2]
MMP -1 for the inhibition of biosynthesis
Human fibroblasts (Lonza, Switzerland), a primary cell directly isolated from neonatal foreskin, were cultured in a 48-well plate incubator at a concentration of 10 4 , and after 24 hours, 10 ng / ml of TNF- The medium was replaced with medium containing 10 ug / ml each. On the second day of culture, the supernatant was harvested and the amount of type I collagenase produced using the ELISA (AP biotech RPN2610) method was quantitated. Each value was expressed as a relative value with the value of the control group treated with TNF-α alone as 100 (Table 2 and FIG. 2).
As can be seen from the above Table 2 and FIG. 2, it was confirmed that the weedy berry extract or its fraction can reduce the biosynthesis of the matrix metalloprotease (MMP) caused by TNF- ?.
[ Experimental Example 3] Gelatinase A ( MMP -9) and Gelatinase B ( MMP -2) to inhibit the biosynthesis and to measure the inhibitory effect
Human keratinocytes (human keratinocytes (HaCaT) donated to Dr. Fusenig of Deutsches Krebsforschungszentrum) were cultured in a 24-well plate incubator at a concentration of 1 × 10 4 and irradiated with ultraviolet B at 30 mJ / cm 2 after 24 hours Then, each of the test substances in Table 3 was replaced with a medium containing 10 ug / ml. After 48 hours of incubation, the supernatant was harvested and subjected to zymography using gelatin gel. The amount of secreted MMP-2 and MMP-9 produced was then measured using a densitometer (Image J is a public domain Java image processing program inspired by NIH Image).
In order to examine the effect of the above activity, the supernatant was diluted with gelatin gel, and then renaturation was carried out in buffer A for 30 minutes. Then, the buffer B and the sample were simultaneously treated and developed, And measured by a ceteometer. Each value was expressed as a relative value with a value of the control group irradiated with only the ultraviolet ray B as 100 (Table 3 and Figs. 3 to 4).
As a result, as shown in Table 3 and Figs. 3 and 4, the weevastrum extract or its fraction inhibited the biosynthesis or activity of MMP-2 and MMP-9, thereby protecting the epidermis-dermis boundary and preventing decomposition, Reduction of skin elasticity, enhancement of elasticity, and enhancement of skin adhesion.
[ Experimental Example 4] Elastase ( Elastase ) Effect on activity
Human leukocyte elastase (HNE, Sigma, E8140 (1 U)) was prepared by adding 1 ml of 0.2 M Tris-Cl (pH 8.0) to 1 vial to make 1 U / ml and incubating the substrate (N- (Methoxysuccinyl) Ala-Pro-Val 4-nitroanilide (M4765) MW 590.6) was made to 120 mM in DMSO and diluted to 1 mM with 0.2 M Tris-Cl (pH 8.0) Only 2 mM was added. After incubation for 10 minutes with 0.2 M Tris-Cl in the 96-well plate and each of the test substances and enzyme shown in Table 4 below, the substrate was incubated at room temperature for 30 minutes. The amount of p-nitroanilide decomposed was measured at 405 nm And the absorbance was measured.
Succinyl-Ala-Ala-Ala-Ala-Ala-Ala) was prepared by adding 3X of pancreatic elastase (PPE, Sigma (E1250 Ala-p-nitroanilide (S4760) MW: 451.4) was made up to 6 mM in 0.2 M Tris-Cl (pH 8.0) and finally added at 2 mM. To a 96 well plate was added 0.2 M Tris- After adding water and enzyme for 10 minutes, the substrate was placed and reacted at room temperature for 30 minutes. The amount of p-nitroanilide decomposed was measured by absorbance at 405 nm. The results are shown in Tables 4 and 5 below.
Inhibition rate (%)
Inhibition rate (%)
As a result, as shown in Table 4 and FIG. 5, it was confirmed that the weasel berry extract or its fraction inhibited the elastase activity and prevented the skin elasticity from lowering.
[ Experimental Example 5]
Pillar Green ( filaggrin ) And Inboluklein ( involucrin ) Expression measurement
Human keratinocytes (Lonza, Switzerland), which was directly isolated from the epidermis of the newborn, were cultured in a 100-fold dish at 10 6 concentrations, and each extract and fraction was replaced with a medium containing 10 ug / ml. After 24 hours of culture, the cells were harvested to obtain proteins, and the amount of protein was quantified using a BCA kit (Pierce Biotechnology, USA). The amounts of filaggrin and Involucrin produced using the Western Blot method were quantified. The western blot was prepared by loading 30 μg of protein per lane on an SDS-PAGE gel, electrophoresing, and transferring the protein to a PVDF membrane (Amersham (USA)) using a protein transfer kit (Invitrogen, USA) , USA). After transfer, the antibody to pillacreen and inbolucrin (Santacruz Biotechnology, USA) was attached to the primary antibody for 1 hour at 37 ° C, washed three times with PBS, and the secondary antibody with HRP was incubated at 37 ° C for 1 hour After being washed three times with PBS, the degree of luminescence was exposed to the film using an ECL kit, and the intensity of the band was quantitated using a densitometer. Each value is a relative value obtained by taking the value of the untreated group as 100.
As a result, as shown in Table 5 and FIG. 6, it was confirmed that the weedy berry extract or fraction can increase the biosynthesis amount of natural moisturizing factors, filaggrin and inbolucurin, in keratinocytes.
[ Experimental Example 6]
Aquaporin 3 gene expression
Human keratinocytes (Lonza, Switzerland), which were directly isolated from the epidermis of the newborn, were cultured in a 100-fold dish at a concentration of 10 6 , and each extract or fraction was replaced with a medium containing 10 ug / ml. Twenty-four hours later, total RNA was extracted using trizol, and the expression level of Aquaporin 3 gene was confirmed by RT-PCR. Reverse transcription was performed using a commercially available reverse transcription system (Promega). The denaturation at 94 ° C for 1 min, the annealing at 54 ° C, 1 minute and extension at 72 ° C for 1 minute in total for 30 cycles. The primers used in the PCR are as follows.
Aquaporin 3
Forward 5 'gacagaaggagctggtgtcc 3'
Reverse 5 'atgaggatgcccagagtgac 3'
GAPDH
Forward 5 'accacagtccatgccatcac 3'
Reverse 5 'tccaccaccctgttgctgta 3'
After the completion of the PCR, the resulting products were loaded on an agarose gel, electrophoresed, stained with ethidium bromide, and the resulting band was measured in the presence of ultraviolet light. The intensity was measured with a densitometer densitometer). The respective values were expressed as relative values when the untreated group was taken as 100 (Table 6 and FIG. 7).
Expression level
As a result, as shown in Table 6 and FIG. 7, it was confirmed that the expression of the aquaporin gene, which is a protein involved in water and glycerin transfer, was increased by treatment of the weedy berry extract or fraction.
The composition of the present invention can be applied to various formulations as described below, but the present invention is not limited thereto.
[Formulation Example 1] Tablets
100 mg of ferret extract or fraction, 100 mg of glucose, 50 mg of red ginseng extract, 96 mg of starch and 4 mg of magnesium stearate were mixed and 40 mg of 30% ethanol was added thereto to form granules. The granules were then dried at 60 ° C., And tableted by tableting.
[Formulation Example 2]
The granules were formed by mixing 100 mg of the extract of the weevastrum syrup or fractions, 100 mg of glucose, 50 mg of red ginseng extract and 600 mg of starch and 100 mg of 30% ethanol, followed by drying at 60 ° C to form granules, Respectively. The final weight of the contents was 1 g.
[Formulation Example 3] Drug agent
100 mg of ferret extract or fraction, 10 g of glucose, 50 mg of red ginseng extract, 2 g of citric acid and 187.8 g of purified water were mixed and filled in a bottle. The final volume of the contents was adjusted to 200 ml.
[Formulation Example 4] Preparation of health food
Weasel berry extract or fraction .................................... 1000 mg
Vitamin mixture
Vitamin A Acetate ....................... 70 ㎍
Vitamin E ............................................ 1.0 mg
Vitamin B1 ........................................... 0.13 mg
Vitamin B2 .......................................... 0.15 mg
Vitamin B6 ........................................... 0.5 mg
Vitamin B12 .............................. 0.2 g
Vitamin C ............................................. 10 mg
Biotin ................................................. 10 [mu] g
Nicotinic acid amide .................................. 1.7 mg
Folic acid ................................................. ..... 50 μg
Calcium pantothenate .................................... 0.5 mg
Mineral mixture
Ferrous sulfate .......................................... 1.75 mg
Zinc oxide ............................................ 0.82 mg
Magnesium carbonate ...................................... 25.3 mg
Potassium Phosphate ......................................... 15 mg
Secondary calcium phosphate ...................................... 55 mg
Potassium citrate ............................................ 90 mg
Calcium carbonate .............................................. 100 mg
Magnesium chloride ..................................... 24.8 mg
Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.
[Formulation Example 5] Preparation of health drinks
Weasel berry extract or fraction ................................ 1000 mg
Citric acid ................................................. ... 1000 mg
oligosaccharide................................................. .... 100 g
Plum concentrate ................................................ ..... 2 g
Taurine ................................................. ........... 1 g
Purified water was added to the mixture to complete 900 ml
The above components were mixed according to a conventional health drink manufacturing method, and the mixture was heated at 85 DEG C for about 1 hour with stirring, and the solution thus prepared was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, ≪ / RTI >
[Formulation Example 1] Lotion
[Formulation Example 2] Cream
[Formulation Example 3] Pack
[Formulation Example 4]
[Formulation Example 5] Ointment
While the present invention has been particularly shown and described with reference to specific embodiments thereof, those skilled in the art will readily appreciate that many modifications are possible in the exemplary embodiments without materially departing from the novel teachings and advantages of this invention. something to do. Accordingly, the actual scope of the present invention will be defined by the appended claims and their equivalents.
<110> KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
<120> COMPOSITION CONTAINING AMORPHA FRUTICOSA EXTRACT
<130> 14P363IND
<160> 4
<170> Kopatentin 2.0
<210> 1
<211> 20
<212> DNA
<213> Aquaporin 3-forward
<400> 1
Claims (11)
Wherein the composition improves skin wrinkles, delays skin wrinkle formation, or prevents skin wrinkle formation.
Wherein the composition improves skin elasticity.
Wherein said composition inhibits the synthesis of a matrix metalloprotease, gelatinease or elastase, or inhibits their activity.
Wherein the composition promotes the synthesis of pillar green or phosphorylcholine or enhances their activity.
Wherein the composition increases the expression of aquaporin.
Wherein the composition comprises from 0.001 to 10% by weight of a fermented broccoli extract, based on the total weight of the composition.
Wherein the composition is a cosmetic composition.
Wherein the composition is a pharmaceutical composition.
Wherein the composition is a health food composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140081151A KR20160002539A (en) | 2014-06-30 | 2014-06-30 | Composition containing amorpha fruticosa extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020140081151A KR20160002539A (en) | 2014-06-30 | 2014-06-30 | Composition containing amorpha fruticosa extract |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150165755A Division KR20160008121A (en) | 2015-11-25 | 2015-11-25 | Composition containing amorpha fruticosa extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20160002539A true KR20160002539A (en) | 2016-01-08 |
Family
ID=55170434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020140081151A KR20160002539A (en) | 2014-06-30 | 2014-06-30 | Composition containing amorpha fruticosa extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20160002539A (en) |
-
2014
- 2014-06-30 KR KR1020140081151A patent/KR20160002539A/en not_active Application Discontinuation
Non-Patent Citations (1)
| Title |
|---|
| Exp Dermatol. 20, 595-599, 2011 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101312965B1 (en) | The cosmetic composition for anti-wrinkle comprising the mixture of extract of Allium cepa, Symphytum officinale, Eclipta prostrate, and Theobroma cacao | |
| KR102088728B1 (en) | Cosmetic Composition for Improving Skin Elasticity and Winkles Comprising Plant Complex Extracts as Active Ingredient | |
| KR20190088286A (en) | Composition for improving skin beauty comprising extract of fermented soybean fermented with Aspergillus cristatus strain | |
| JP2006219432A (en) | Composition having rough skin-preventing activity, cosmetic and beverage | |
| KR102299276B1 (en) | Compositions containing oils of glycine gracilis | |
| KR101449282B1 (en) | Composition for improving skin wrinkle and skin moisturing comprising Barley fermented by Pichia jadinii and Aureobasidium pullulans bacteria | |
| KR102189415B1 (en) | Compositions for preventing or improving the UV-induced skin damage comprising the extract of Eisenia bicyclis as an active ingredient | |
| KR101914441B1 (en) | Cosmetic compositions for improving skin moisturizing comprising fucosterol | |
| KR101904501B1 (en) | Cosmetic compositions for improving skin wrinkles or skin elasticity comprising fucosterol | |
| KR20090132285A (en) | Cosmetic composition containing fruit vinegar | |
| KR101446295B1 (en) | Composition for anti-aging containing sargassum yezoense extract | |
| KR102238329B1 (en) | Skin funtional composition containing fermented natural product complex by lactic acid | |
| KR102337346B1 (en) | Cosmetic composition containing extract of Pinus rigida Mill. for antioxidative or anti-aging | |
| KR102196051B1 (en) | Skin functional composition containing fermented artemisia capillaris | |
| KR101956666B1 (en) | Composition for improving wrinkle comprising Aneilema keisak Hand.-Mazz. extract and use thereof | |
| KR20220073062A (en) | Cosmetic composition for improving skin barrier function and anti-wrinkle effects comprising fermented eggplant extract as an active ingredient | |
| KR102014961B1 (en) | Composition for anti oxidation containing extract of soybean pod | |
| KR20160002539A (en) | Composition containing amorpha fruticosa extract | |
| CN115919698B (en) | Composition with tightening and anti-wrinkle effects and application thereof | |
| KR20200024464A (en) | Antioxidation and whitening active composition containing complex seaweed fermented extract | |
| KR102014960B1 (en) | Composition for anti oxidation containing extract of soybean root | |
| KR20160008121A (en) | Composition containing amorpha fruticosa extract | |
| KR102532713B1 (en) | Novel Saccharomyces cerevisiae strain and use thereof | |
| KR20130136602A (en) | Cosmetic composition from field waterdrop extract and its fermentation | |
| KR20010096634A (en) | A compositions for skin external application containing the sap of bamboo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| A107 | Divisional application of patent | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |